Zolunicant

Zolunicant (MM-110) is a potent nicotinic α3β4 receptor inhibitor with an IC50 of 0.90 μM, showing promise in combating addiction. It effectively reduces self-administration of addictive agents such as morphine, cocaine, methamphetamine, nicotine, and ethanol in rat models, indicating its potential as a treatment for various forms of drug abuse [1]. Additionally, Zolunicant exhibits strong leishmanicidal activity against Leishmania amazonensis, expanding its therapeutic prospects [2].